Biden Administration Under Fire For Ignoring "The Science"

WaPo |  The U.S. government, over the past few weeks, has made three important decisions on vaccines without consulting independent panels of experts. On Nov. 19, the Food and Drug Administration authorized boosters for all adults — regardless of their job or any underlying health conditions. On Nov. 29, the Centers for Disease Control and Prevention announced that everyone 18 and above should get a booster shot, a revision of previous guidance that strongly recommended boosters only for those 50 and older. Then, on Dec. 9, the FDA authorized booster shots (of Pfizer) for 16- and 17-year-olds, moving the age of eligibility down from 18.

Before last month, the standard practice was for the agencies to convene standing outside advisory committees, whose members inspect the relevant data, debate it and vote. That did not happen in these cases, meaning that the costs and benefits of these policy moves, from a medical perspective, were not fully aired publicly and discussed in advance.

One of us is the former deputy director of the FDA’s Office of Vaccines Research and Review; the other is a former acting chief scientist at the FDA. We believe that much is lost when decisions like these are made without consulting outside experts — whatever one believes about the merits of the policies in question.

At this point in the pandemic, the world faces a host of new questions related to vaccines and boosting. The recommendations of experts on the outside advisory committees are needed more than ever — so the scientific community can understand the empirical bases for decisions, and so the public can be assured that science, not politics, is driving vaccine policy.

Facing omicron feels like when a patient has relapsed

In each of the recent decisions we’ve mentioned, at least some experts would probably have voiced opposition (based on earlier scientific debates and votes the two committees had taken, which supported different conclusions). That these experts were not given a chance to make their cases could hurt the credibility of these agencies. (In a poll published in May, conducted by the Robert Wood Johnson Foundation and the Harvard T.H. Chan School of Public Health, 75 percent of American adults said they trusted the FDA a great deal or somewhat, with 24 percent saying they felt not much trust or none.)

This area of research is fast-moving, and much changed between the most recent meetings of the expert committees (on the booster question) and the FDA’s decision to authorize boosters for 16- and 17-year-olds — notably the emergence of the omicron variant. Still, the lack of involvement of the FDA’s expert panel on that question was striking, and observers noticed. Helen Branswell, a senior writer for the health and science publication STAT News, tweeted that the FDA had “authorized Pfizer booster shots for 16- & 17-years olds, without asking its vax expert panel for advice.” She added, “This approach sidesteps what would likely have been lengthy discussion about myocarditis” — an uncommon side effect of the mRNA vaccines, which had drawn careful study in earlier steps of the approval process.

In a news release, the FDA explained that it didn’t convene the outside committee because approving boosters for 16- and 17-year-olds “does not raise questions that would benefit from additional discussion by committee members.” But that is unpersuasive, given the previously expressed views of panel members. The CDC has not explained why it did not convene its own panel of vaccine experts for its recent decision.